Simone Cursiefen

Learn More
BACKGROUND Natalizumab has been recommended for the treatment of relapsing-remitting multiple sclerosis (RRMS) in patients with insufficient response to interferon-beta/glatiramer acetate (DMT) or aggressive MS. The pivotal trials were not conducted to investigate natalizumab monotherapy in this patient population. METHOD Retrospective, multicenter study(More)
PURPOSE To analyze the association of normal-pressure glaucoma and migraine. METHODS In a prospective study, 154 patients with glaucoma (56 normal-pressure subgroup and 98 high-pressure glaucoma subgroup), 55 patients with ocular hypertension, and 75 control subjects were analyzed by means of a standardized questionnaire based on International Headache(More)
BACKGROUND Proximal myotonic myopathy is an autosomal dominant multisystem disorder with a recently defined CCTG expansion on chromosome 3 in the major subgroup (myotonic dystrophy type 2). Cardiac rhythm disturbances have been described in patients with this disease, but it is not known whether myotonic dystrophy type 2/proximal myotonic myopathy patients(More)
Mitoxantrone is an anthracenedione anti-neoplastic agent that has recently been shown to be effective in ameliorating disease activity in multiple sclerosis (MS) as indicated by clinical and MRI data. However, the role of mitoxantrone in escalating treatment of patients with frequent and severe relapses and with rapid progression of disability is less(More)
Myoclonus is a symptom characterized by involuntary, short-lasting, sometimes repetitive irregular muscular activity of sudden onset. Myoclonus can be generated at all levels of the nervous system and is associated with a variety of neurological diseases and syndromes [1]. We present the case of a 41-year old right-handed patient with a 1-year history of(More)
Schwer verlaufende Formen der multiplen Sklerose (MS) mit mehreren Schüben pro Jahr und inkompletter Remission oder mit rasch progredientem Verlauf und drohendem Verlust der Gehfähigkeit erfordern den Einsatz intensiver immuntherapeutischer Maßnahmen. Die Wirksamkeit von Mitoxantron bei der MS konnte in kontrollierten Studien nachgewiesen werden, doch(More)
  • 1